A comprehensive review of studies indicates that antihistamines, commonly prescribed for eczema symptoms, provide no significant benefit and may potentially lead to increased harms. This finding addresses long-standing uncertainty regarding their efficacy in managing the prevalent skin condition.
New Study Challenges Antihistamine Use for Eczema
Experts have broadly welcomed the findings, which call for a reassessment of current medical guidance for eczema. The condition, also known as atopic dermatitis, affects a substantial portion of the UK population, with an estimated one in five children and one in ten adults experiencing its effects.
Despite existing recommendations that advise against routine use, approximately 20% of eczema patients in the UK currently take antihistamines. While NICE guidance permits their use in specific instances, such as when flare-ups are associated with hives or other allergic reactions, or for short-term sedation to manage sleep disturbance due to severe itching, the new research casts doubt on their general effectiveness.
Evidence Against Antihistamine Efficacy
A review conducted by Canadian experts, encompassing 47 trials involving over 6,200 individuals with moderate to severe eczema, compared antihistamines against a placebo. The results indicated that antihistamines led to a "clinically unimportant reduction" in eczema severity and itchiness.
Furthermore, the study suggests that these medications may not effectively reduce sleep disturbance or eczema flare-ups. First-generation antihistamines, often associated with drowsiness, also carry the risk of cognitive impairment and may prompt patients to discontinue treatment due to adverse side effects.
Potential for Treatment Revolution in Edinburgh
Researchers publishing in the BMJ stated their findings, which indicate antihistamines likely do not improve patient outcomes while "probably increasing harms," provide a foundation for evidence-based changes in clinical practice. They advocate for updated atopic dermatitis guidelines that prioritise efficacy, safety, and patient-centred care.
In parallel, a significant development at Edinburgh's Heriot-Watt University promises to potentially revolutionise eczema diagnosis and treatment. A new vibroacoustic sensor technology, having secured over £475,000 in funding, employs small skin vibrations to measure underlying tissue stiffness and fluid content, offering a more objective assessment than traditional visual evaluations. Professor Michael Crichton described the sensor as a "fundamental shift" in eczema management, particularly noting its advantage for patients with darker skin tones where visual assessments can be unreliable.
